Cargando…
Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability
BACKGROUND: The novel cystic fibrosis transmembrane conductance regulator (CFTR) modulators, ivacaftor, lumacaftor, and tezacaftor, are the first drugs directly targeting the underlying pathophysiological mechanism in cystic fibrosis (CF); however, independent studies describing their pharmacokineti...
Autores principales: | Vonk, Steffie E. M., van der Meer-Vos, Marloes, Bos, Lieuwe D. J., Neerincx, Anne H., Majoor, Christof J., Maitland-van der Zee, Anke-Hilse, Mathôt, Ron A. A., Kemper, E. Marleen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Therapeutic Drug Monitoring
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277188/ https://www.ncbi.nlm.nih.gov/pubmed/33165217 http://dx.doi.org/10.1097/FTD.0000000000000829 |
Ejemplares similares
-
Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients
por: Neerincx, Anne H., et al.
Publicado: (2021) -
Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
por: Schwarz, Carsten, et al.
Publicado: (2021) -
Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients
por: Kos, Renate, et al.
Publicado: (2022) -
Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019) -
Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)